



E-mail jelly3636@hotmail.com



Li Jiang Commercialization of the gene-edited crop and morality: challenges from liberal patent law and strict GMO law in the EU ⑧. /7 *New Genetic and Society* (SSCI-indexed) (forthcoming)

Li Jiang Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent (2018) *Science and Engineering Ethic* (SSCI-indexed) (<https://link.springer.com/article/10.1007%2Fs11948-018-0043-3>)

Li Jiang and Rosemann Achim Human embryo gene editing in China: the uncertain legal status of the embryo 2019 14 *BioSocieties* 46-66. (SSCI-indexed)

Li Jiang Centralised Intellectual Property Administrative Management Reform in China: Why it is needed and whether it works (2018) 111 *Intellectual Property Forum* 19-24

Achim Rosemann, Xinqing Zhang and **Li Jiang**, Human Germ Line Gene Editing: Why Comparative, Cross-National Studies of Public Viewpoints are Important (2017) 5 *Anthropology* 175-178.

Li Jiang and Binghe Dong Fraudsters Operate and Officialdom Turns a Blind Eye: a Proposal for Controlling Stem Cell Therapy in China (2016) 19 *Medicine, Health Care and Philosophy* 403-410. (SSCI-indexed)

Li Jiang, Will Wild East End Scientific Feast-the First Administrative Measure on Clinical Stem Cell Research in China (2016) 35 *Biotechnology Law Report* 27-35. (SCI-indexed)

Li Jiang B C B C A 8
A C (2015) 25 *DePaul Journal of Art, Technology and Intellectual Property Law* 53-90.

Li Jiang @ A 8
C A 2015 6 *American University Intellectual Property Brief* 53-97.

Li Jiang and Wei D 8 C
Harmoniz C A (2014) 97 *Intellectual Property Forum* 63-68.

Achim Rosemann, **Li Jiang** and Xinqing Zhang The Regulatory and Legal Situation of Human Embryo, Gamete and Germ Line Gene Editing Research and Clinical Applications in



the People's Republic of China, Nuffield Bioethics Committee, UK, 2017.

Li Jiang The Regulation of Clinical Stem Cell in China in Phuc Pham & Achim Rosemann (ed.), *Stem Cells in Clinical Application: Safety, Ethics and Regulation*, Springer (2017)

Li Jiang, Patentability of Human Embryo Stem Cell: A Comparative Analyse of Case WARF in United States and Europe in H. B. Singh, A. Jha and C. Keswani (ed.), *Intellectual Property Issues in Biotechnology*, CABI (2016)

Reviewer, Asia Pacific Law Review

Reviewer, Stem Cell Translational Medicine

Reviewer, Pharmaceutical Patent Analyst